Dec 7, 2006 by Brian LawlerThe Best Small Cap for 2007: Encysive PharmaceuticalsThis little drug maker has the potential for big profit, in both the U.S. and Europe.
Dec 5, 2006 by Brian LawlerSlight Setback for OnyxOnyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder.
Dec 5, 2006 by Brian LawlerCubist Finds an Asian PartnerThe company teams up with AstraZeneca to bring its antibiotic to worldwide markets.
Dec 4, 2006 by Brian LawlerSuccess for DynavaxSolid results from the first of three phase III trials cause Dynavax's shares to rise.
Dec 4, 2006 by Brian LawlerI Think Axcan, I Think AxcanThis small pharma is quietly growing earnings.
Nov 30, 2006 by Brian LawlerDurect's Pain-Free DealA partnership deal has investors in the small specialty pharma excited.
Nov 30, 2006 by Brian LawlerNot Bad, BayerThe company's buyout of fellow German firm Schering AG looks like a boon to its bottom line.
Nov 29, 2006 by Brian LawlerBiotech Is Not for the Weak of HeartBut you can make serious money from this exciting sector.
Nov 27, 2006 by Brian LawlerRoche Says Goodbye to PDLThe larger pharmaceutical drops out of daclizumab development.
Nov 27, 2006 by Brian LawlerTeva and Pfizer Make UpThe companies decide to play nice over generic versions of two of Pfizer's drugs.
Nov 27, 2006 by Brian LawlerPharmaxis Gets Good News From the FDAFast-track designation gives this stock a bump.
Nov 24, 2006 by Brian LawlerHow to Get Your Financial Future StartedSome advice for recent college graduates.
Nov 24, 2006 by Brian LawlerAmylin Gets Past the FormalitiesFollowing a formal approval from the EU for Byetta, Amylin can get down to business.
Nov 22, 2006 by Brian LawlerImplant Approval Gives Allergan a LiftThe return of silicone breast implants continues.
Nov 22, 2006 by Brian LawlerActelion's Adept AcquisitionThe pharmaceutical buys CoTherix, streamlining sales of both firms' PAH treatments.
Nov 22, 2006 by Brian LawlerHow to Market a Drug Too WellCephalon's promotion of its pain drug Actiq might have crossed the line.
Nov 22, 2006 by Brian LawlerDueling Fools: Johnson & Johnson Bear RebuttalThe bottom line is top-line growth -- specifically, the lack thereof.
